Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Potential biomarkers to follow the progression and treatment response of Huntington's disease.

The Journal of experimental medicine - 14 Nov 2016

Disatnik Marie-Hélène, Joshi Amit U, Saw Nay L, Shamloo Mehrdad, Leavitt Blair R, Qi Xin, Mochly-Rosen Daria

Abstract excerpt

Huntington's disease (HD) is a rare genetic disease caused by expanded polyglutamine repeats in the huntingtin protein resulting in selective neuronal loss. Although genetic testing readily identifies those who will be affected, current pharmacological treatments do not prevent or slow down disease progression. A major challenge is the slow clinical progression and the inability to biopsy the affected tissue, the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aldehydes
Share to Behavior, Animal

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Body Fluids

Share to Huntington Disease

Share to Inflammation

Share to Muscle, Skeletal

Share to Oxidation-Reduction

Share to Protein Aggregates

Source

Open in PubMed Open full text

Identifiers

PMID: 27821553
DOI: 10.1084/jem.20160776
PMCID: PMC5110026

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Potential biomarkers to follow the progression and treatment response of Huntington's disease.PMID 27821553Read ↗

What, When and How to Measure-Peripheral Biomarkers in Therapy of Huntington's Disease.Semantic proximity Read ↗

Huntington disease: new insights into molecular pathogenesis and therapeutic opportunities.Semantic proximity Read ↗

Abnormal molecular signatures of inflammation, energy metabolism and vesicle biology in human Huntington disease peripheral tissuesSemantic proximity Read ↗

Increased survival and neuroprotective effects of BN82451 in a transgenic mouse model of Huntington's diseaseSemantic proximity Read ↗

Abnormal molecular signatures of inflammation, energy metabolism, and vesicle biology in human Huntington disease peripheral tissuesSemantic proximity Read ↗

Antioxidant and Anti-Inflammatory Defense in Huntington’s Disease: Role of NRF2 and Pgc-1α and Therapeutic StrategiesSemantic proximity Read ↗

Antioxidant and Anti-Inflammatory Defenses in Huntington’s Disease: Roles of NRF2 and PGC-1α, and Therapeutic StrategiesSemantic proximity Read ↗

Bim contributes to the progression of Huntington's disease-associated phenotypes.Semantic proximity Read ↗

Oxidative damage in Huntington's disease.Semantic proximity Read ↗

Mutant huntingtin fragmentation in immune cells tracks Huntington's disease progression.Semantic proximity Read ↗

Methylene blue modulates huntingtin aggregation intermediates and is protective in Huntington's disease models.Semantic proximity Read ↗

XJB-5-131-mediated improvement in physiology and behaviour of the R6/2 mouse model of Huntington's disease is age- and sex- dependent.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.